Trends in patient characteristics and mortality among Medicare patients diagnosed with peripheral artery disease.

IF 3 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE
Xavier Fowler, Kunal Mehta, Mark Eid, Barbara Gladders, Stephen Kearing, Kayla O Moore, Mark A Creager, Andrea M Austin, Mark W Feinberg, Marc P Bonaca, Philip Greenland, Mary M McDermott, Philip P Goodney
{"title":"Trends in patient characteristics and mortality among Medicare patients diagnosed with peripheral artery disease.","authors":"Xavier Fowler, Kunal Mehta, Mark Eid, Barbara Gladders, Stephen Kearing, Kayla O Moore, Mark A Creager, Andrea M Austin, Mark W Feinberg, Marc P Bonaca, Philip Greenland, Mary M McDermott, Philip P Goodney","doi":"10.1177/1358863X241262330","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Peripheral artery disease (PAD) is a well-described risk factor for mortality, but few studies have examined secular trends in mortality over time for patients with PAD. We characterized trends in mortality in patients with PAD in recent years among Medicare patients.</p><p><strong>Methods: </strong>We used Medicare claims to identify patients with a new diagnosis code for PAD between January 1, 2006 and December 31, 2018 using International Classification of Diseases (ICD) diagnosis codes. The primary outcome of interest was the 1-year all-cause age-adjusted mortality rate. Our secondary outcome was the 5-year all-cause mortality rate. Multivariable regression was used to identify factors which predict mortality at 1 year.</p><p><strong>Results: </strong>We identified 4,373,644 patients with a new diagnosis code for PAD during the study period. Between 2006 and 2018, 1-year all-cause age-adjusted mortality declined from 12.6% to 9.9% (<i>p</i> < 0.001). One-year crude all-cause mortality also declined from 14.6% to 9.5% (<i>p</i> < 0.001). Similar results were observed for 5-year age-adjusted mortality rates (40.9% to 35.2%, <i>p</i> < 0.001). Factors associated with increased risk of death at 1 year included age ⩾ 85 years (hazard ratio [HR] 3.030; 95% CI 3.008-3.053) and congestive heart failure (HR 1.86; 95% CI 1.85-1.88). Patients who were regularly dispensed statins, ace-inhibitors, beta-blockers, antithrombotic agents, and anticoagulants all had lower mortality (range OR 0.36; CI 0.35-0.37 for statins to OR 0.60; CI 0.59-0.61 for anticoagulants; all <i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>Among US Medicare patients diagnosed with PAD between 2006 and 2019, 1-year age-adjusted mortality declined by 2.7%. This decline in mortality among PAD patients occurred in the context of a younger mean age of diagnosis of PAD and improved cardiovascular prevention therapy.</p>","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1358863X241262330","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Peripheral artery disease (PAD) is a well-described risk factor for mortality, but few studies have examined secular trends in mortality over time for patients with PAD. We characterized trends in mortality in patients with PAD in recent years among Medicare patients.

Methods: We used Medicare claims to identify patients with a new diagnosis code for PAD between January 1, 2006 and December 31, 2018 using International Classification of Diseases (ICD) diagnosis codes. The primary outcome of interest was the 1-year all-cause age-adjusted mortality rate. Our secondary outcome was the 5-year all-cause mortality rate. Multivariable regression was used to identify factors which predict mortality at 1 year.

Results: We identified 4,373,644 patients with a new diagnosis code for PAD during the study period. Between 2006 and 2018, 1-year all-cause age-adjusted mortality declined from 12.6% to 9.9% (p < 0.001). One-year crude all-cause mortality also declined from 14.6% to 9.5% (p < 0.001). Similar results were observed for 5-year age-adjusted mortality rates (40.9% to 35.2%, p < 0.001). Factors associated with increased risk of death at 1 year included age ⩾ 85 years (hazard ratio [HR] 3.030; 95% CI 3.008-3.053) and congestive heart failure (HR 1.86; 95% CI 1.85-1.88). Patients who were regularly dispensed statins, ace-inhibitors, beta-blockers, antithrombotic agents, and anticoagulants all had lower mortality (range OR 0.36; CI 0.35-0.37 for statins to OR 0.60; CI 0.59-0.61 for anticoagulants; all p < 0.001).

Conclusion: Among US Medicare patients diagnosed with PAD between 2006 and 2019, 1-year age-adjusted mortality declined by 2.7%. This decline in mortality among PAD patients occurred in the context of a younger mean age of diagnosis of PAD and improved cardiovascular prevention therapy.

被诊断患有外周动脉疾病的医疗保险患者的特征和死亡率趋势。
简介:外周动脉疾病(PAD)是一种公认的死亡风险因素,但很少有研究调查 PAD 患者死亡率的长期趋势。我们描述了近年来医疗保险(Medicare)患者中 PAD 患者的死亡率趋势:我们利用医疗保险报销单,使用国际疾病分类(ICD)诊断代码识别了 2006 年 1 月 1 日至 2018 年 12 月 31 日期间有 PAD 新诊断代码的患者。我们关注的主要结果是 1 年全因年龄调整后死亡率。我们的次要结果是 5 年全因死亡率。多变量回归用于确定预测 1 年死亡率的因素:在研究期间,我们确定了 4,373,644 名新诊断代码为 PAD 的患者。2006 年至 2018 年间,经年龄调整后的 1 年全因死亡率从 12.6% 降至 9.9%(p < 0.001)。1年粗略全因死亡率也从14.6%降至9.5%(p < 0.001)。经年龄调整后的 5 年死亡率也出现了类似的结果(从 40.9% 降至 35.2%,p < 0.001)。与 1 年死亡风险增加相关的因素包括年龄⩾ 85 岁(危险比 [HR] 3.030;95% CI 3.008-3.053)和充血性心力衰竭(HR 1.86;95% CI 1.85-1.88)。定期服用他汀类药物、王牌抑制剂、β-受体阻滞剂、抗血栓药和抗凝剂的患者死亡率均较低(他汀类药物的OR值为0.36;CI值为0.35-0.37,抗凝剂的OR值为0.60;CI值为0.59-0.61;所有P均小于0.001):在2006年至2019年期间被诊断为PAD的美国医疗保险患者中,经年龄调整后的1年死亡率下降了2.7%。PAD患者死亡率的下降是在PAD诊断平均年龄年轻化和心血管预防治疗得到改善的背景下发生的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Vascular Medicine
Vascular Medicine 医学-外周血管病
CiteScore
5.70
自引率
5.70%
发文量
158
审稿时长
>12 weeks
期刊介绍: The premier, ISI-ranked journal of vascular medicine. Integrates the latest research in vascular biology with advancements for the practice of vascular medicine and vascular surgery. It features original research and reviews on vascular biology, epidemiology, diagnosis, medical treatment and interventions for vascular disease. A member of the Committee on Publication Ethics (COPE)
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信